The drugs that the participants were taking at the baseline and end point
| Baseline | End point | |||
|---|---|---|---|---|
| N | (%) | N | (%) | |
| Antidiabetic agents | ||||
| Insulin | 158 | (45.1) | 196 | (56.0) |
| Pioglitazone | 63 | (18.0) | 103 | (29.4) |
| Biguanide | 147 | (42.0) | 207 | (59.1) |
| DPP4I | – | (–) | 83 | (23.7) |
| Sulfonylurea | 107 | (30.6) | 62 | (17.7) |
| Glinide | 9 | (2.6) | 92 | (26.3) |
| AGI | 68 | (19.4) | 133 | (38.0) |
| Antihypertensive agents | ||||
| RASI therapy | 144 | (41.1) | 208 | (59.4) |
| Mono | 123 | 131 | ||
| Double | 21 | 62 | ||
| Triple | 0 | 15 | ||
| CCBs therapy | 71 | (20.3) | 174 | (49.7) |
| Mono | 65 | 117 | ||
| Double | 6 | 45 | ||
| Triple | 0 | 12 | ||
| Diuretics therapy | 37 | (10.6) | 68 | (19.4) |
| Mono | 36 | 46 | ||
| Double | 1 | 18 | ||
| Triple | 0 | 4 | ||
| β-blockers | 17 | (4.9) | 42 | (12.0) |
| Others | 19 | (5.4) | 44 | (12.6) |
| Antihyperlipidemic agents | ||||
| Statin | 76 | (21.7) | 121 | (34.6) |
AGI, α-glucosidase inhibitors; CCBs, calcium channel blockers; DPP4I, dipeptidyl peptidase inhibitors; RASI, renin-angiotensin system inhibitors.